Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities, limiting treatment uptake.To assess the all-oral 3 direct-acting antiviral (3D)...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Mark Sulkowski, Joseph J. Eron, David Wyles, Roger Trinh, Jay Lalezari, Chia Wang, Jihad Slim, Laveeza Bhatti, Joseph Gathe, Peter Ruane, Richard Elion, Fritz Bredeek, Robert T. Brennan, Gary Blick, Amit Khatri, Krystal Gibbons, Yiran Hu, Linda Fredrick, Gretja Schnell, Edward Tam, Rakesh Tripathi, Barbara Da Silva‐Tillmann, Barbara McGovern, Andrew Campbell, Thomas Podsadecki
Fformat: Artigo
Iaith:Saesneg
Cyhoeddwyd: 2015
Mynediad Ar-lein:https://doi.org/10.1001/jama.2015.1328
https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Rhyngrwyd

https://doi.org/10.1001/jama.2015.1328
https://jamanetwork.com/journals/jama/articlepdf/2173265/joi150019.pdf

Eitemau Tebyg